• Recruiting

NCT05028348: Phase 3: EMN 29 - Selinexor, Pom, Dex (SPd) Vs Elotuzumab, Pom, Dex in RRMM Myeloma

Updated: Sep 25

EMN 29

NCT05028348: Phase 3: A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma


emn29

A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma


This phase 3 randomized, open-label multicenter trial will compare the efficacy, safety and the impact on health-related quality of life (HR-QoL) of SPd versus EloPd in pomalidomide-naïve patients with MM who have received 1 to 4 prior anti-MM regimens and been treated with an immunomodulatory imide drug (IMiD), proteasome inhibitor (PI) and an anti-CD38 monoclonal antibody (mAb).


Sponsor

European Myeloma Network


Collaborator

Karyopharm Therapeutics Inc


Multiple Locations

International Study

 

ClinicalTrials.gov Identifier: NCT05028348

Official Title: A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

First Posted : August 31, 2021


Click here for ClinicalTrials.gov


EMN29 - European Myeloma Network (myeloma-europe.org)

 

Selinexor : National Cancer Institute

Selinexor : MedlinePlus Drug Information

 

Drug: Selinexor

Drug: Elotuzumab

Drug: Pomalidomide

Drug: Dexamethasone Oral

 

Locations

Europe

France

Germany

Greece

Italy

Netherlands

Spain

Posts Archive